Answers are grounded in this paper and cite their sources.
Rhabdomyolysis is a clinical syndrome in which skeletal muscle damage and necrosis leads to the release of intracellular muscle contents, which can ultimately lead to electrolyte disturbances, renal failure and even death. Chemotherapy is an extremely rare cause of rhabdomyolysis. Herein, we describe a fatal case of rhabdomyolysis in a patient with metastatic sarcoma after receiving the chemotherapeutic agent Ecteinascidin-743 (ET-743, trabectedin) as palliative chemotherapy treatment.
No takes yet. Share an insight, caveat, or question.
Skorupa et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: